About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Phase 2 Trial of JKN24011 in COPD

NCT07440524·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Joincare Pharmaceutical Group Industry Co., Ltd

JKN24011 targets TSLP

Age

40–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Written informed consent; able and willing to comply with study procedures.
Adults with documented COPD diagnosis and medical history consistent with guideline criteria.
Relevant exposure history consistent with COPD (e.g., smoking and/or biomass exposure).
On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.
Protocol-defined exacerbation history, symptom burden, and lung function at screening.

You may not be if

Current or past asthma, or other clinically significant respiratory disease that may confound assessment.
Clinically significant uncontrolled comorbidities that increase risk or interfere with participation/outcomes.
Immunodeficiency/immune dysregulation, active autoimmune disease requiring systemic immunosuppression, or significant opportunistic infection history.
Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined COPD exacerbation.
Current/recent malignancy (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.
Prohibited recent vaccines or therapies, prior relevant biologic/targeted therapy exposure, severe hypersensitivity to biologics/IMP, pregnancy/breastfeeding, or inability to comply (including substance abuse), per investigator judgment.

The record

StatusCompleted

PhasePhase 2

Taking part215

StartedAug 2024

UpdatedOct 15, 2026

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Where1

Huadong Hospital, Fudan University
Shanghai, China